Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Epidermal growth factor receptor inhibition in aerodigestive carcinomas

This week's Journal of the American Medical Association investigates epidermal growth factor receptors as therapeutic targets in aerodigestive carcinomas.

News image

fiogf49gjkf04

Malignancies arising from the aerodigestive epithelium, including lung, head and neck, and esophageal carcinomas, are the leading causes of cancer-related mortality worldwide.

The biological importance of epidermal growth factor receptor in cancer development and progression has been established.

Because of this, epidermal growth factor receptor inhibitors have emerged as promising novel therapies.

Dr Michalis Karamouzis and colleagues from Pennsylvania, USA summarized the current status of epidermal growth factor receptor inhibitors in aerodigestive carcinomas.

The team have highlighted ongoing research designed to optimize their therapeutic effectiveness, and consider the future role of these agents.

The research team performed a systematic MEDLINE search of English-language literature 1966 to 2007.

Multiple epidermal growth factor receptor inhibition strategies are under evaluation
Journal of the American Medical Association

The team used the terms epidermal growth factor receptor, epidermal growth factor receptor inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors.

Search terms including lung cancer, head and neck cancer, esophageal cancer, and epidermal growth factor receptor predictive factors were also used.

Quality assessment of selected studies included clinical pertinence.

To minimize bias, the team considered controlled study design, and publication in peer-reviewed journals.

Adequate number of enrolled patients, objectivity of measurements, and techniques used were also assessed by the researchers.

The team found that the role of the epidermal growth factor receptor in aerodigestive carcinomas pathogenesis has been extensively studied.

The researchers observed that multiple epidermal growth factor receptor inhibition strategies are under evaluation.

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor used as a single agent has shown survival benefit in 1 trial of patients with advanced non-small cell lung cancer.

The team noted that cetuximab, an anti- epidermal growth factor receptor monoclonal antibody used in combination with radiation, has also conferred survival benefit in 1 trial of patients with locally advanced head and neck squamous cell carcinoma.

However, other trials have not shown these degrees of improvement.

Epidermal growth factor receptor inhibitors toxicities include rash, diarrhea, and hypomagnesemia.

Somatic mutations and other molecular tumoral characteristics offer opportunities for treatment individualization and optimal patient selection for anti-epidermal growth factor receptor therapy.

Dr Karamouzis' team commented, "Epidermal growth factor receptor is a promising therapeutic target in aerodigestive carcinomas."

"Further translational research is needed to optimize ways of inhibiting epidermal growth factor receptor using single-agent or combination regimens and to identify patients who benefit the most from these therapies."

JAMA 2007: 298(1): 70-82
05 July 2007

Go to top of page Email this page Email this page to a colleague

 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 11 May 2018 
Depressive symptoms in IBD youth
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
PPI use and cognitive decline
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Fecal incontinence and quality of life in IBD
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 24 April 2018 
PPI and risk of stroke
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 20 April 2018 
Worldwide H.pylori prevalence
 19 April 2018 
c-Myc expression and pancreatic cancer
 19 April 2018 
Olmesartan prescription in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us